OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial

Burosumab, a fully human IgG1 monoclonal antibody to FGF23, is approved in Canada and Brazil to treat XLH in patients ≥1 year of age and in the US to treat XLH in patients ≥6 months of age. Burosumab has also received conditional marketing authorization in Europe to treat XLH with radiographic evide...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Endocr Soc
Main Authors: Perwad, Farzana, Portale, Anthony A, Carpenter, Thomas O, Briot, Karine, Imel, Erik Allen, Kamenicky, Peter, Weber, Thomas Joseph, Pitukcheewanont, Pisit, Cheong, Hae Il, De Beur, Suzanne Marie Jan, Imanishi, Yasuo, Ito, Nobuaki, Lachmann, Robin, Tanaka, Hiroyuki, Zhang, Lin, Skrinar, Alison, Rees, Linda, Insogna, Karl Leonard
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2020
Fag:
Bone and Mineral Metabolism
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209551/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.147
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker